How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dcl-101-vs-golytely.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

DCL-101 vs Golytely — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DCL-101 vs Golytely (DCL-101 vs Golytely) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: KRAS G12C inhibitor. Area: Oncology.

phase 2 KRAS G12C inhibitor KRAS G12C Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DCL-101 vs Golytely (DCL-101 vs Golytely) — Dark Canyon Laboratories, LLC. DCL-101 is a small molecule that targets the KRAS G12C mutation, inhibiting the KRAS protein's ability to promote cancer cell growth.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DCL-101 vs Golytely TARGET	DCL-101 vs Golytely	Dark Canyon Laboratories, LLC	phase 2	KRAS G12C inhibitor	KRAS G12C
AMG 510	AMG 510	Criterium, Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C
MRTX849	MRTX849	Mirati Therapeutics Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C
RMC-6236	RMC-6236	Revolution Medicines, Inc.	phase 3	KRAS G12C inhibitor	KRAS G12C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (KRAS G12C inhibitor class)

Criterium, Inc. · 1 drug in this class
Dark Canyon Laboratories, LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
Revolution Medicines, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DCL-101 vs Golytely — Competitive Intelligence Brief. https://druglandscape.com/ci/dcl-101-vs-golytely. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing